Galectin-3: A novel protein in cerebellar: Hemangioblastoma

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 5, 2013, Pages 853-861

  Al Salam, Suhail ^a   Al Salam, Mohammed ^b   Ashari, Moueid Al ^c  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b MUSTANSIRIYAH UNIVERSITY   (Iraq)

^c TAWAM HOSPITAL   (United Arab Emirates)

Author keywords

CNS neoplasms; Galectin 3; Hemangioblastoma; Hif

Indexed keywords

GALECTIN 3; GALECTIN-3, HUMAN; TUMOR MARKER;

BIOSYNTHESIS; CEREBELLUM TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HEMANGIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM;

CEREBELLAR NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; GALECTIN 3; HEMANGIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84883154960     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hussein MR, Central nervous system capillary hemangioblastoma: the pathologist's viewpoint. Int J Exp Pathol 2007; 88: 311-324
2. Ishizawa K, Komori T, Hirose T. Stromal cells in hemangioblastoma: neuroectodermal differentiation and morphological similarities to ependymoma. Pathol Int 2005; 55: 377-385
3. Lantos PL, Louis DN, Rosenblum MK, Kleihues P. Tumours of the nervous system. In: Graham DI, Lantos PL, editors. Greenfield's Neuropathology, 7th edition. London: Arnold 2002; pp: 767-1052
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109
5. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins: structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807-20810
6. Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med 2010; 207: 1981-1993
7. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-1480
8. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ. Genomewide Association of Hypoxia-inducible Factor (HIF)-1 and HIF-2 DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts. J Biol Chem 2009; 284: 16767-16775
9. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helixloophelix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514
10. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. HIF alpha targeted for VHL mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-468
11. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275
12. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 2001; 15: 1312-1314
13. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008; 15: 621-627
14. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006; 66: 6264-6270
15. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulinlike growth factor 2. Cancer Res 1999; 59: 3915-3918
16. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/ PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-1545
17. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Bürgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 2002; 512: 157-162
18. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001; 276: 9519-9525
19. Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A. Activated pp 60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J Biol Chem 2002; 277: 42919-42925
20. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E. Upregulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005; 206: 291-304
21. Zeng Y, Danielson KG, Albert TJ, Shapiro IM, Risbud MV. HIF-1alpha is a Regulator of Galectin-3 Expression in the Intervertebral Disc. J Bone Miner Res 2007; 22: 1851-61
22. Koch AE, Halloran MM, Haskel CJ, Shah NR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule 1. Nature 1995; 376: 517-519
23. Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G. Hypoxic induction of anHIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 2006; 107: 2705-2712
24. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000; 156: 899-909
25. McCarty G, Awad O, Loeb DM. WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J Biol Chem 2011; 286: 43634-43
26. Wang Y, Pakunlu RI, Tsao W, Pozharov V, Minko T. Bimodal effect of hypoxia in cancer: role of hypoxia inducible factor in apoptosis. Mol Pharm 2004; 1: 156-165
27. Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Del Bufalo D. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One 2010; 5: e11772.